Drugs / DT402
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07303907 | Dec 2025 → Aug 2027 expected | autism spectrum disorder | Definium Therapeutics US, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07303907 ↗ |